Search research articles
Contact Us
Filters
Showing results (51-60 of 79) with videos related to
Page
of 8
Sort By:
Urologic Oncology
|
January 25, 2016
Body mass index and age are additional prognostic factors in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors
Yan Song, Chunxia Du, Wen Zhang, et al.
Asia-Pacific Journal of Clinical Oncology
|
March 22, 2016
A study on the association between hyperlipidemia and hypothyroidism and the response to TKIs in metastatic renal cell carcinoma
Yan Song, Chunxia Du, Wen Zhang, et al.
Signal Transduction and Targeted Therapy
|
April 9, 2026
Irinotecan with trifluridine/tipiracil and bevacizumab for second-line metastatic colorectal cancer: a phase II multicenter study
Wenwei Yang, Jing Zhang, Ping Liang, et al.
Journal of Hematology & Oncology
|
October 8, 2016
Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors
Yongkun Sun, Wei Niu, Feng Du, et al.
Bio-Medical Materials and Engineering
|
October 2, 2012
Interaction between titanium and phosphoproteins revealed by chromatography column packed with titanium beads
Yoshinori Kuboki, Toshitake Furusawa, Masaaki Sato, et al.
Hepatology International
|
April 7, 2021
Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase II study (ALTER-0802 study)
Yongkun Sun, Aiping Zhou, Wen Zhang, et al.
Materials Today. Bio
|
April 18, 2024
Trilayered biomimetic hydrogel scaffolds with dual-differential microenvironment for articular osteochondral defect repair
Hongying Chen, Jinyi Huang, Xiaomeng Li, et al.
International Journal of Cancer
|
December 26, 2025
Efficacy and safety of fruquintinib combined with albumin-bound paclitaxel as second-line therapy for advanced gastric cancer following failure of PD-1 inhibitor-containing treatment (TACTIC GC-01): A phase II single-arm study
Xiaoting Ma, Kai Ou, Xiu Liu, et al.
BMC Cancer
|
January 3, 2024
Regorafenib monotherapy or combined with an immune-checkpoint inhibitor as later-line treatment for metastatic colorectal cancer: a multicenter, real-world retrospective study in China
Wang Qu, Zimin Liu, Xiaobing Chen, et al.
Medicine
|
June 11, 2015
S-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer: A Randomized, Open-Label Phase 2 Trial
Feng Du, Zhaoxu Zheng, SuSheng Shi, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 79) with videos related to
Sort By:
Page
of 8
Urologic Oncology
|
January 25, 2016
Body mass index and age are additional prognostic factors in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors
Yan Song, Chunxia Du, Wen Zhang, et al.
Asia-Pacific Journal of Clinical Oncology
|
March 22, 2016
A study on the association between hyperlipidemia and hypothyroidism and the response to TKIs in metastatic renal cell carcinoma
Yan Song, Chunxia Du, Wen Zhang, et al.
Signal Transduction and Targeted Therapy
|
April 9, 2026
Irinotecan with trifluridine/tipiracil and bevacizumab for second-line metastatic colorectal cancer: a phase II multicenter study
Wenwei Yang, Jing Zhang, Ping Liang, et al.
Journal of Hematology & Oncology
|
October 8, 2016
Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors
Yongkun Sun, Wei Niu, Feng Du, et al.
Bio-Medical Materials and Engineering
|
October 2, 2012
Interaction between titanium and phosphoproteins revealed by chromatography column packed with titanium beads
Yoshinori Kuboki, Toshitake Furusawa, Masaaki Sato, et al.
Hepatology International
|
April 7, 2021
Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase II study (ALTER-0802 study)
Yongkun Sun, Aiping Zhou, Wen Zhang, et al.
Materials Today. Bio
|
April 18, 2024
Trilayered biomimetic hydrogel scaffolds with dual-differential microenvironment for articular osteochondral defect repair
Hongying Chen, Jinyi Huang, Xiaomeng Li, et al.
International Journal of Cancer
|
December 26, 2025
Efficacy and safety of fruquintinib combined with albumin-bound paclitaxel as second-line therapy for advanced gastric cancer following failure of PD-1 inhibitor-containing treatment (TACTIC GC-01): A phase II single-arm study
Xiaoting Ma, Kai Ou, Xiu Liu, et al.
BMC Cancer
|
January 3, 2024
Regorafenib monotherapy or combined with an immune-checkpoint inhibitor as later-line treatment for metastatic colorectal cancer: a multicenter, real-world retrospective study in China
Wang Qu, Zimin Liu, Xiaobing Chen, et al.
Medicine
|
June 11, 2015
S-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer: A Randomized, Open-Label Phase 2 Trial
Feng Du, Zhaoxu Zheng, SuSheng Shi, et al.
Page
of 8